Clinical studies on s 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections

Seiichi Aonuma; Kotaro Oizumi; Akira Watanabe; Yutaka Tokue; Yoshihiro Honda; Reiko Ono; Naoto Kitamura; Kiyoshi Konno

doi:10.11553/antibiotics1968b.41.1309

Clinical studies on s 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections

Seiichi Aonuma, Kotaro Oizumi, Akira Watanabe, Yutaka Tokue, Yoshihiro Honda, Reiko Ono, Naoto Kitamura, Kiyoshi Konno

Research output: Contribution to journal › Article › peer-review

Abstract

S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg de-vided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80^. There were no side effects or abnormal laboratory findings due to administration of this drug.

Original language	English
Pages (from-to)	1309-1312
Number of pages	4
Journal	the japanese journal of antibiotics
Volume	41
Issue number	9
DOIs	https://doi.org/10.11553/antibiotics1968b.41.1309
Publication status	Published - 1988 Jan 1

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.41.1309

Cite this

@article{f0bb710b260e43649bc42d4bc2d18937,

title = "Clinical studies on s 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections",

abstract = "S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg de-vided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80^. There were no side effects or abnormal laboratory findings due to administration of this drug.",

author = "Seiichi Aonuma and Kotaro Oizumi and Akira Watanabe and Yutaka Tokue and Yoshihiro Honda and Reiko Ono and Naoto Kitamura and Kiyoshi Konno",

year = "1988",

month = jan,

day = "1",

doi = "10.11553/antibiotics1968b.41.1309",

language = "English",

volume = "41",

pages = "1309--1312",

journal = "The Journal of antibiotics. Ser. B",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "9",

}

TY - JOUR

T1 - Clinical studies on s 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections

AU - Aonuma, Seiichi

AU - Oizumi, Kotaro

AU - Watanabe, Akira

AU - Tokue, Yutaka

AU - Honda, Yoshihiro

AU - Ono, Reiko

AU - Kitamura, Naoto

AU - Konno, Kiyoshi

PY - 1988/1/1

Y1 - 1988/1/1

N2 - S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg de-vided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80^. There were no side effects or abnormal laboratory findings due to administration of this drug.

AB - S 6472 granule preparation (sustained-release cefaclor) was orally administered to 15 patients with chronic respiratory tract infections (2 acutely exacerbated cases of chronic bronchitis, 13 cases of secondary infections consisting of 1 case of bronchial asthma, 2 cases of bronchial asthma/pulmonary emphysema, and 10 cases of bronchiectasis) at a daily dose of 750 mg de-vided into 2 doses administered after breakfast and dinner, for a duration of 14 days. The drug was ineffective in 3 of the 10 cases of bronchiectasis but was effective in the other 12 cases, with a rate of efficacy of 80^. There were no side effects or abnormal laboratory findings due to administration of this drug.

UR - http://www.scopus.com/inward/record.url?scp=0023795025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023795025&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.41.1309

DO - 10.11553/antibiotics1968b.41.1309

M3 - Article

C2 - 3241329

AN - SCOPUS:0023795025

VL - 41

SP - 1309

EP - 1312

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 9

ER -

Clinical studies on s 6472 granule preparation (sustained-release cefaclor) in chronic respiratory tract infections

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this